Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14) - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Current Oncology Year : 2021

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)

Abstract

Concomitant radiochemotherapy (RTCT) is the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). However, in patients with a peripheral primary tumor, the irradiated volume may include a large portion of normal lung and RT-CT is not possible. This multicenter phase II trial in unresectable stage III NSCLC with peripheral primary tumor evaluated the feasibility of stereotactic body radiation therapy (SBRT) in peripheral tumor after concomitant radio-chemotherapy (RT-CT). Nineteen patients were included and analyzed (median age, 60.9 years; male, 78%; adenocarcinoma, 74%; median size of peripheral primary tumor, 19 mm). At 6 months, the disease control rate was 79% (15/19). SBRT toxicity was generally mild with one (5%) patient having grade 3 lung toxicity. Recruitment for this study was stopped prior to completion, firstly due to the approval of adjuvant durvalumab after RT-CT, which was not anticipated in the design, and secondly due to the small number of stage III NSCLC patients with a peripheral tumor that was accessible to SBRT. Nevertheless, the combination of RT-CT and SBRT appeared to be feasible and safe.
Fichier principal
Vignette du fichier
curroncol-28-00324.pdf (526.52 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-04142094 , version 1 (26-06-2023)

Identifiers

Cite

Isabelle Martel-Lafay, Isabelle Monnet, Audrey Lardy-Cleaud, Serge Danhier, Naji Salem, et al.. Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14). Current Oncology, 2021, 28 (5), pp.3804-3811. ⟨10.3390/curroncol28050324⟩. ⟨hal-04142094⟩
4 View
7 Download

Altmetric

Share

Gmail Facebook X LinkedIn More